Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
Yoshihiko WataraiRomina DanguilanConcesa CasasolaShen-Shin ChangPrajej RuangkanchanasetrTerence Kee Yi ShernHin Seng WongTakashi KenmochiAngel Joaquin AmanteKuo-Hsiung ShuAtiporn IngsathitPeter BernhardtMaria Pilar Hernandez-GutierrezDuck-Jong HanMyoung Soo KimPublished in: Clinical transplantation (2021)
This subgroup analysis in Asian de novo KTxRs demonstrated that the EVR+rCNI versus MPA+sCNI regimen provides comparable antirejection efficacy, better renal function, and reduced viral infections (NCT01950819).